TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Eql Pharma AB
Closing information (x1000 EUR)
| Closing information | 2024/03 (consolidated) | 2023/03 (consolidated) | 2022/03 (consolidated) |
| Turnover |
22,921
|
23,050
|
39,634 |
| Financial expenses |
497
|
210
|
278 |
| Earnings before taxes |
2,482
|
3,456
|
3,479 |
| EBITDA |
3,590
|
4,401
|
4,354 |
| Total assets |
32,430
|
25,337
|
23,010 |
| Current assets |
17,160
|
14,830
|
11,941 |
| Current liabilities |
14,061
|
10,285
|
9,552 |
| Equity capital |
15,421
|
13,724
|
11,958 |
| - share capital |
113
|
116
|
127 |
| Employees (average) |
21
|
18
|
13 |
Financial ratios
| Fiscal year | 2024/03 (consolidated) | 2023/03 (consolidated) | 2022/03 (consolidated) |
| Solvency |
47.6%
|
54.2%
|
52.0% |
| Turnover per employee |
1,091
|
1,281
|
3,049 |
| Profit as a percentage of turnover |
10.8%
|
15.0%
|
8.8% |
| Return on assets (ROA) |
9.2%
|
14.5%
|
16.3% |
| Current ratio |
122.0%
|
144.2%
|
125.0% |
| Return on equity (ROE) |
16.1%
|
25.2%
|
29.1% |
| Change turnover |
369
|
-13,288
|
22,306 |
| Change turnover % |
2%
|
-37%
|
129% |
| Chg. No. of employees |
3
|
5
|
3 |
| Chg. No. of employees % |
17%
|
38%
|
30% |
Total value of public sale
| Fiscal year | 2024/03 (consolidated) | 2023/03 (consolidated) | 2022/03 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.